If You Invested in Helus Pharma Inc. (HELP)
Looking for the current price? See the HELP quote & overviewWhat $1,000 or $10,000 in HELP Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Nov 11, 2020 |
|---|---|---|---|---|
| $1,000 | $1,498 +50% | $118 -88% | — | $340 -66% |
| $10,000 | $14,983 +50% | $1,179 -88% | — | $3,398 -66% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-06. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for HELP$1,000 Investment Over Time
HELP vs S&P 500Year-by-Year Returns
HELP annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2020Nov 11, 2020 to Dec 31, 2020 | $26.37 | $56.62 | +114.7% | +114.7% |
| 2021 | $56.62 | $45.60 | -19.5% | +72.9% |
| 2022 | $45.60 | $11.29 | -75.3% | -57.2% |
| 2023 | $11.29 | $15.58 | +38.0% | -40.9% |
| 2024 | $15.58 | $8.82 | -43.4% | -66.6% |
| 2025 | $8.82 | $8.18 | -7.3% | -69.0% |
| 2026Dec 31, 2025 to Nov 6, 2026 | $8.18 | $8.96 | +9.5% | -66.0% |
About Helus Pharma Inc.
Healthcare · NASDAQ
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company developing proprietary neuroactive compounds for mental health conditions. The company describes these compounds as novel serotonergic agonists, or NSAs: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. Its listed securities trade under the symbol HELP on Nasdaq and Cboe Canada.
The company's development work is centered on depression, anxiety, and other mental health conditions. Its lead disclosed program, HLP003, is a proprietary NSA in clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004 is a proprietary NSA in clinical development for generalized anxiety disorder. Helus Pharma also reports a broader research portfolio of investigational NSAs.
Helus Pharma's business model is organized around pharmaceutical research and clinical development rather than commercial product sales. Its operating activities include advancing investigational compounds through clinical programs, engaging with regulators, building medical and scientific capabilities, and supporting clinical research participation for its mental health pipeline. The company has described operations in Canada, the United States, the United Kingdom, and Ireland.
As a public clinical-stage issuer, Helus Pharma's corporate record includes pipeline updates, clinical and regulatory disclosures, governance changes, capital-structure matters, and operating and financial results. The company was formerly known to public markets as Cybin Inc. while using Helus Pharma as its commercial operating name.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Helus Pharma Inc. investment returns
How much would $1,000 invested in Helus Pharma Inc. be worth today?
If you invested $1,000 in Helus Pharma Inc. (HELP) 5 years ago on 2021-11-08, your investment would be worth $118 as of 2026-11-06, a -88.2% price return without dividends, growing at a compounded rate of -34.8% per year (CAGR).
Has Helus Pharma Inc. outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare HELP performance over available time periods.
What is Helus Pharma Inc.'s average annual return?
The compound annual growth rate (CAGR) of HELP’s share price over the past 5 years is -34.8%, without dividends. Individual years vary a great deal, and HELP’s best recent full year was 2023 (+38.0%) while the worst was 2022 (-75.3%).
For informational and educational purposes only, not investment advice.
